Page last updated: 2024-09-02

ecteinascidin 743 and Carcinoma

ecteinascidin 743 has been researched along with Carcinoma in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adam, JP; Boumedien, F; Letarte, N; Provencher, D1
Amadio, G; Carpano, S; Ferrandina, G; Loizzi, V; Lorusso, D; Marinaccio, M; Naglieri, E; Salutari, V; Scambia, G; Tonini, G; Vincenzi, B1
González Martín, A1
Comisso, M; Koeppel, F; Larsen, AK; Poindessous, V; Raymond, E; Waters, SJ1
De Pooter, CM; Faircloth, GT; Korst, AE; Lambrechts, HA; Lardon, F; Pattyn, GG; Simoens, C; Vermorken, JB1

Reviews

1 review(s) available for ecteinascidin 743 and Carcinoma

ArticleYear
Safety profile of trabectedin in combination with liposomal pegylated doxorrubicin in relapsed ovarian carcinoma: considerations for optimal management.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21 Suppl 1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dioxoles; Doxorubicin; Female; Humans; Liposomes; Ovarian Neoplasms; Patient Compliance; Quality of Life; Recurrence; Tetrahydroisoquinolines; Trabectedin

2011

Other Studies

4 other study(ies) available for ecteinascidin 743 and Carcinoma

ArticleYear
Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
    Gynecologic oncology, 2017, Volume: 147, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma; Dioxoles; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin

2017
Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study.
    Gynecologic oncology, 2013, Volume: 130, Issue:3

    Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Asthenia; Carcinoma; Dioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Platinum Compounds; Retrospective Studies; Salvage Therapy; Tetrahydroisoquinolines; Trabectedin

2013
Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:7

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Carcinoma; Cell Line, Tumor; Cisplatin; Culture Media; Dioxoles; Drug Resistance, Neoplasm; Epithelial Cells; Glutamate-Cysteine Ligase; Glutathione Transferase; Humans; Isoquinolines; Models, Chemical; Plant Extracts; Polycyclic Sesquiterpenes; rho GTP-Binding Proteins; Sesquiterpenes; Tetrahydroisoquinolines; Time Factors; Trabectedin; Tumor Suppressor Protein p53

2003
In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects.
    British journal of cancer, 2003, Dec-15, Volume: 89, Issue:12

    Topics: Antineoplastic Agents, Alkylating; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dioxoles; Humans; Isoquinolines; Lung Neoplasms; Radiation-Sensitizing Agents; Tetrahydroisoquinolines; Tongue Neoplasms; Trabectedin; Urinary Bladder Neoplasms

2003